Contents

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia (REPAIR)

March 1, 2013

Clinical trial

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.

Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A.

Eye (Lond). 2013 Jun;27(6):709-15.
Full text | Metrics.

Main finding: There was a significant improvement in BCVA and central macular thickness at 6 months in patients receiving intravitreal ranibizumab for myopic CNV.

 

  • Purpose: To evaluate the safety and efficacy of intravitreal ranibizumab in myopic CNV
  • Study type: Phase 2 single arm study
  • Condition: Myopic Choroidal Neovascularization

Participants: Age ≥18 years with active primary or recurrent subfoveal/juxtafoveal myopic CNV
-high myopia (at least -6.0dioptres)

 

  • n=65 patients

 

Intervention:

 

Intravitreal Ranibizumab 0.5mg followed by monthly injections as needed for up to 11 months

Interim analysis:

 

-Mean BCVA improved from baseline by 12.2 letters

 

-Fewer patients had centre-involving intraretinal oedema (13.0% vs 91.5%), intraretinal cysts (10.9% vs 57.4%), or subretinal fluid (13.0% vs 66.0%) at 6 months than at baseline

 

-Patients received a mean of 1.9 retreatments

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed